What is the recommended dosing, contraindications, side effects, and monitoring for nicorandil tablets in an adult with chronic stable angina?

Nicorandil for Chronic Stable Angina in Adults

Recommended Dosing

Nicorandil should be initiated at 20 mg twice daily for the prevention of angina in adults with chronic stable angina. 1

• A lower starting dose of 5 mg twice daily may be used to minimize headache, then titrated upward as tolerated 2
• The therapeutic dose range is 10-40 mg per dose, typically administered twice daily 3
• Dosing should be maintained on a twice-daily schedule to provide sustained anti-anginal efficacy without development of tolerance 3

Place in Therapy

Nicorandil is a second-line or alternative agent, not a first-line therapy for stable angina. 1, 2

Treatment Algorithm:

1. First-line: Beta-blockers (e.g., atenolol 100 mg daily, metoprolol CR 200 mg daily, bisoprolol 10 mg daily) 1

2. When beta-blockers are contraindicated or not tolerated, consider these alternatives:

   • Ivabradine (Class IIa, Level A) 2
   • Long-acting nitrates (Class IIa, Level A) 2
   • Amlodipine (Class IIa, Level A) 2
   • Nicorandil (Class IIb, Level C) 1, 2

3. When symptoms persist despite beta-blocker monotherapy:

   • Add a dihydropyridine calcium channel blocker (Class I, Level B) 1
   • OR substitute with nicorandil if calcium channel blocker combination is unsuccessful (Class IIa, Level C) 1

4. Special indication - Vasospastic angina:

   • Nicorandil may be useful as third-line therapy (5 mg twice daily) after failure of calcium channel blockers and long-acting nitrates 2

Absolute Contraindications

Co-administration with phosphodiesterase-5 inhibitors (sildenafil, tadalafil, vardenafil) is absolutely contraindicated due to risk of life-threatening hypotension (Class I, Level C). 2, 4

• Cardiogenic shock or severe hypotension 2
• If a patient requires PDE-5 inhibitor therapy, nicorandil must be discontinued and replaced with an alternative anti-anginal agent (beta-blocker, ivabradine, amlodipine, or ranolazine) before any PDE-5 inhibitor can be prescribed 4

Relative Contraindications and Precautions

Do NOT combine nicorandil with nitrates - this combination lacks additional efficacy and increases adverse effects 2

• Do NOT combine with ivabradine or ranolazine - safety of these combinations is unknown 2
• Use with extreme caution in heart failure - safety remains uncertain in this population 2
• Caution with aspirin co-administration - may increase risk of gastrointestinal ulcers, perforations, and hemorrhage 2, 5

Common Side Effects

Headache is the most common adverse effect, occurring in approximately one-third of patients. 5, 6

• Headache is typically mild-to-moderate, most frequent at treatment initiation, and declines with continued use 6
• Approximately 5% of patients withdraw due to headache; this can be reduced by starting at 5 mg twice daily 6
• In the IONA trial, 39% of patients withdrew, primarily due to headache 5

Other Common Side Effects:

• Facial flushing (due to vasodilation) 5
• Hypotension 5
• Tachycardia (compensatory response to vasodilation) 5
• Reflux 5

Serious but Rare Side Effects

Serious skin, mucosal, and eye ulceration have been reported, though rare. 2, 5

• Gastrointestinal ulcers, perforations, and hemorrhage (especially when combined with aspirin) 2, 5

Monitoring Requirements

For oral therapy: No specific routine monitoring is required beyond standard angina symptom assessment 1

For IV nicorandil (acute coronary syndromes):

• Continuous blood pressure and heart rate monitoring during infusion 2
• Titrate dose until anginal symptoms are relieved or adverse effects emerge 2
• Promptly evaluate and discontinue if signs of hypotension (dizziness, syncope) appear 2

IV Dosing (Acute Settings):

• Bolus: 2-14 mg 2
• Continuous infusion: titrated to clinical response 2

Clinical Efficacy Evidence

The IONA trial (5,126 patients) demonstrated that nicorandil reduced the composite endpoint of cardiovascular death, non-fatal MI, and unplanned hospitalization from 15.5% to 13.1% (HR 0.83; 95% CI 0.72-0.97; p=0.014). 2

• However, nicorandil did NOT significantly reduce coronary heart disease mortality or non-fatal MI alone (HR 0.79; 95% CI 0.61-1.02; p=0.068) 2
• Benefits were primarily driven by reduction in unplanned hospitalization for unstable angina, not mortality 2
• Comparative trials show nicorandil is equivalent in efficacy to isosorbide dinitrate, propranolol, atenolol, nifedipine, and diltiazem for stable angina 6, 7

Mechanism and Unique Properties

Nicorandil has a dual mechanism: potassium channel activation (arterial vasodilation) plus a nitrate moiety (venodilation). 1, 6

• Unlike pure nitrates, tolerance to anti-anginal effects may develop but cross-tolerance with nitrates does not occur 1
• Thought to have cardioprotective properties through potassium channel activation and potential ischemic preconditioning 1, 2, 6

Key Clinical Pitfalls to Avoid

1. Never prescribe with PDE-5 inhibitors - this is an absolute contraindication that can cause fatal hypotension 2, 4
2. Avoid combining with nitrates - no added benefit and increased side effects 2
3. Do not use as first-line therapy - beta-blockers remain first-line due to mortality benefit 1, 2
4. Start low (5 mg BID) in headache-prone patients to improve tolerability 2, 6
5. Exercise caution in heart failure - safety profile is uncertain in this population 2